nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-DCB73F5B·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Genetics·Basis: Full text·Type: Computational simulation

Cell type-specific contextualisation of the human phenome: towards the systematic treatment of all rare diseases.

Schilder et al.Schilder, Murphy, Dash et al.·2026·Genome medicine·10.1186/s13073-026-01692-0 ↗

Primary claim

We identified significant associations between 201 cell types and 9,575/11,028 (86.7%) phenotypes across 8,628 RDs, substantially expanding knowledge of phenotype-cell type links.

Tentative · broad association coverage with unreconciled denominators, moderate replication and no precision estimate for novel links
In brief

A valuable phenome-scale rare-disease resource whose therapeutic promise is constrained by unvalidated causal inference and internally inconsistent validation statistics.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

BACKGROUND: Rare diseases (RDs) are a highly heterogeneous and underserved group of conditions. Most RDs have a strong genetic basis but their causal pathophysiological mechanisms remain poorly understood, limiting the development of targeted therapies.

METHODS: We systematically characterised the cell type-specific mechanisms underlying all genetically defined RD phenotypes by integrating the Human Phenotype Ontology (HPO) with whole-body single-cell transcriptomic atlases from embryonic, foetal, and adult samples. Associations were validated against orthogonal biomedical knowledge graphs and then prioritised by strength of supporting evidence, clinical severity, and gene-therapy compatibility.

RESULTS: We identified significant associations between 201 cell types and 9,575/11,028 (86.7%) phenotypes across 8,628 RDs, substantially expanding knowledge of phenotype-cell type links. Prioritisation by severity (e.g. lethality, motor or mental impairment) and gene-therapy compatibility (e.g. cell type specificity, postnatal treatability) identified candidate phenotypes and cell types for therapeutic targeting.

CONCLUSIONS: We present a scalable, reproducible framework for phenome-wide, cell type-specific mechanism prediction in rare diseases, providing a major step toward systematic therapeutic development for patients across a broad spectrum of serious RDs.

SOFTWARE AND DATA AVAILABILITY: Interactive web portal: https://neurogenomics-ukdri.dsi.ic.ac.uk/ . R packages introduced in this study: KGExplorer ( https://github.com/neurogenomics/KGExplorer ), HPOExplorer ( https://github.com/neurogenomics/HPOExplorer ), and MSTExplorer ( https://github.com/neurogenomics/MSTExplorer ). Manuscript analyses and reproducibility code: https://github.com/neurogenomics/rare_disease_celltyping .

Key Claims

Primary finding · Tentative

We identified significant associations between 201 cell types and 9,575/11,028 (86.7%) phenotypes across 8,628 RDs, substantially expanding knowledge of phenotype-cell type links.

Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

broad association coverage with unreconciled denominators, moderate replication and no precision estimate for novel links

Abstract, Results
Quote verified
Secondary · Supported

All 7 HPO branches showed disproportionate associations with on-target cell types from their respective organ systems.

branch-level ontology matching supports the reported enrichment pattern, though it is an internal positive-control analysis

Results, Validation of expected phenotype-cell type relationships
Quote verified
Secondary · Supported

This yielded putative therapeutic targets for 5,252 phenotypes across 4,819 diseases in 201 cell types and 3,148 genes.

the reported pipeline directly produces these putative outputs, but sequential heuristic filters limit validation of their prioritisation

Results, Therapeutic target identification
Quote verified
Secondary · Tentative

We recapitulated 87% (120 total) of all non-failed existing gene therapy targets, with significant enrichment (p=5.6×10⁻⁵, odds ratio=3.0).

retrospective gene-level overlap is reported, but recovery conflicts with sensitivity and uses a future-dated TTD release

Results, Therapeutic target validation
Secondary · Tentative

Our pipeline implicates M2 macrophages (‘Alternatively activated macrophages’) as the only causal cell type

associative analysis of an incomplete reference atlas cannot establish an exclusive causal cell type

Results, Selected example targets
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Phenome-scale integrated rare-disease resource

The framework connects HPO and GenCC evidence to 201 cell types and reports associations across thousands of phenotypes and diseases, then exposes the results through software and a portal.

↳ Abstract; Results, Phenotype-cell type associations; Methods, Rare Disease Celltyping Portal

#methodological rigour

Multiple complementary validation layers

The study uses organ-system matching, Monarch Knowledge Graph recall and comparisons across two atlases and developmental stages rather than relying on a single internal check.

↳ Results, Validation of expected phenotype-cell type relationships; Validation of inter- and intra-dataset consistency; Validation using biomedical knowledge graphs

#application pathway

Reusable software and access pathway

Three R packages, analysis scripts and an interactive portal support programmatic and non-programmatic reuse by rare-disease researchers and translational teams.

↳ Software and Data Availability; Methods, Novel R packages and Rare Disease Celltyping Portal

Limitations

#methodological rigour

Validation statistics do not reconcile

The consistency analyses report permutation p-values unattainable with 1,000 permutations, and therapeutic-target recovery, sensitivity and failed-target interpretations conflict between the Results and Fig. 8. These discrepancies make exact validation strength unreliable.

↳ Methods and Results, Validation of inter- and intra-dataset consistency; Results, Therapeutic target validation; Fig. 8

#reporting

Causal language exceeds associative design

Regression of curated gene evidence against reference-atlas expression specificity can nominate associations but cannot establish causal or exclusive cell types. Claims such as “only causal cell type” are especially difficult to reconcile with acknowledged atlas omissions.

↳ Methods, Phenotype-cell type associations; Results, Selected example targets; Discussion, Current limitations

#methodological rigour

Benchmarks miss decisive performance questions

The MKG analysis reports recall without precision, the therapeutic benchmark is gene-level rather than cell-type-specific, and sequential target filters are not ablated. The claimed EWCE advantage is also deferred to an external issue rather than demonstrated in the article.

↳ Methods, Phenotype-cell type associations and Therapeutic target identification; Results, Validation using biomedical knowledge graphs and Therapeutic target validation

Does this match your read? Add your assessment ↓

Nabu Commentary

The paper’s strongest contribution is the scale and accessibility of its phenotype–cell-type resource, supported by two atlases, ontology checks, open packages and a web portal. Methodological Rigour is limited by the absence of an in-paper EWCE benchmark, unablated prioritisation filters and validation metrics that do not establish cell-type-specific therapeutic performance. The Results also contain unattainable permutation p-values and conflicting therapeutic-target quantities, requiring correction before the validation strength can be judged reliably. The resource is therefore useful for hypothesis generation, but the article’s causal and therapeutic conclusions need substantial qualification.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.8±0.2

Contribution
3.8

The work meaningfully extends phenotype-to-cell-type analysis to 201 cell types and thousands of rare-disease phenotypes, with software, a portal and a target-prioritisation layer. Its advance is principally one of scale and integration rather than a new causal design.

Abstract; Results, Phenotype-cell type associations and Therapeutic target identification; Methods, Novel R packages

We identified significant associations between 201 cell types and 9,575/11,028 (86.7%) phenotypes across 8,628 RDs

Methodological Rigour
2.3

Two atlases, global FDR correction, ontology checks and public code provide meaningful robustness, but the EWCE comparison is deferred outside the paper and the multi-filter target pipeline is not ablated. MKG recall lacks precision, and therapeutic overlap does not validate the claimed cell-type specificity.

Methods, Phenotype-cell type associations and Therapeutic target identification; Results, Validation using biomedical knowledge graphs and Therapeutic target validation

Precision could not be computed, as MKG lists only true positives.

Reporting
3.0

The progression from association testing through validation and prioritisation is followable. However, repeated causal and therapeutic-development language would lead readers to infer stronger mechanistic and translational evidence than the associative analyses provide.

Abstract, Conclusions; Results, Selected example targets; Conclusions

we systematically nominate causal cell types for thousands of phenotypes

Positioning
2.7

The paper discusses atlas coverage, incomplete gene–phenotype knowledge and reduced power for sparsely annotated phenotypes. Those boundaries are not consistently carried into exclusive causal-cell claims or the asserted scope of the prioritised target list.

Discussion, Current limitations; Results, Selected example targets

Our pipeline implicates M2 macrophages (‘Alternatively activated macrophages’) as the only causal cell type.

Reliability

Caveats4 of 4 checks


Results checkNoted
  • We identified significant associations between 201 cell types and 9,575/11,028 (86.7%) phenotypes across 8,628 RDs, substantially expanding knowledge of phenotype-cell type links: "We identified significant associations between 201 cell types and 9,575/11,028 (86.7%) phenotypes across 8,628 RDs, substantially expanding knowledge of phenotype-cell type links." (Abstract, Results) vs "Across 201 cell types and 11,047 phenotypes, we found >46,514 significant phenotype–cell type relationships" (Discussion). The Abstract fraction gives 9,575/11,028 × 100 = 86.824%, whereas using the Discussion denominator gives 9,575/11,047 × 100 = 86.675%, so the reported 86.7% matches the latter denominator after rounding. → Conclusion holds
  • We recapitulated 87% (120 total) of all non-failed existing gene therapy targets, with significant enrichment (p=5.6×10⁻⁵, odds ratio=3.0): "\begin{document}$$87$$\end{document}% (120 total) of all non-failed existing gene therapy targets" (Results, Therapeutic target validation) vs "\text {sensitivity}$$\end{document}=\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$0.83$$\end{document}" (Results, Therapeutic target validation, non-failed gene-therapy enrichment metrics). Recovery of 87% corresponds to sensitivity 0.87 rather than 0.83 if both quantities use the stated non-failed gene-therapy target set, but the underlying contingency counts needed to determine which figure is correct are not supplied. → Effect on result unclear
Reporting and transparencyNoted

The selected-example introduction announces four examples but lists three.

Data availability: declared · Code availability: declared

Reference IntegrityClean

79 references in manuscript 76 of 76 checkable references found in an index 3 have no canonical index record — counted, but not index-checkable 1 reference confirmed by manual review

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Generic health relevance
Type of advanceMethodological
Route to useNamed
AdvanceExtends
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The association framework is shown working as proof of concept against the Monarch Knowledge Graph benchmark and replicated across two independent scRNA-seq atlases, but no experimental or clinical validation of the predicted cell types exists.

From the paper
“useful for clinicians, biomedical scientists, and pharmaceutical manufacturers who wish to focus their research efforts on phenotypes with the greatest need for intervention”

The paper names the professions (clinicians, biomedical scientists, pharmaceutical manufacturers) and the purpose (prioritising gene-therapy targets and research efforts) but does not specify a concrete decision setting or how they would apply the findings.

Pathway

Pharmaceutical companies and gene-therapy developers would use the prioritised cell type-resolved gene targets to select and design therapies for severe rare diseases.

Barrier

The predicted phenotype-cell type associations and targets are computational nominations that each require wet-lab and clinical validation before any therapeutic can be developed.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. From Uncertainty to Pathogenicity: Resolving a CSF1R Variant of Uncertain Significance Using Long-Read Transcriptomics

    2026 · Clinical medicine

    Primary claim

    Functional evidence allowed reclassification of the variant using American College of Medical Genetics and Genomics (ACMG) and Association for Clinical Genomic Science (ACGS) guidelines from VUS to likely pathogenic, enabling definitive molecular diagnosis.

    Tentative
    Evidence Score
    3.5±0.2
    Reliability
    No concerns
  2. Accelerating scientific discovery with Co-Scientist

    Gottweis, Weng, Daryin, et al. · 2026 · Computer and Information Sciences

    Primary claim

    Co-Scientist helped to identify new drug-repurposing candidates and synergistic combination therapies for acute myeloid leukaemia that were validated through in vitro experiments

    Tentative
    Evidence Score
    3.2±0.1
    Reliability
    Caveats
  3. Tracing the spread of Germanic languages using ancient genomics

    2026 · Biological sciences

    Primary claim

    we identify an archaeologically elusive population that entered Sweden, likely from the Baltic region, by around 4000 bp

    Supported
    Evidence Score
    3.4±0.2
    Reliability
    No concerns

How the rubric works →